Company Profile

Dakocytomation Colorado Inc (AKA: Cytomation GTX Inc)
Profile last edited on: 8/30/2023      CAGE: 3U2F6      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1988
First Award
2000
Latest Award
2003
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4850 Innovation Drive
Fort Collins, CO 80525
   (970) 226-2200
   general@dako.com
   www.dako.com
Location: Single
Congr. District: 02
County: Larimer

Public Profile

Cytomation, Inc., of Fort Collins, CO, is an engineering instrumentation firm founded in 1988 by two Australian scientists. Renamed Dakocytomation Colorado Inc, the firm is now part of the Danish firm Dako - a firms focused to cancer diagnostics through the development, manufacture and marketing of cell-based cancer diagnostics for both clinical diagnostics and research use. A key factor in ensuring patients the best treatment is to make an accurate diagnosis at an early stage. Dako’s products help doctors all over the world to make more precise diagnoses of cancer patients on the basis of reliable test results. Dako aims to improve cancer diagnostics and help create higher productivity and better workflow in hospital and research laboratories. Dako therefore seeks to continuously develop and offer ever more automated and integrated diagnostic systems and products which give the pathologist and laboratory personnel better opportunities to exploit the benefits of both existing forms of treatment and the constantly increasing number of new forms of treatment. Dako is a global business with headquarters in Denmark. It was founded by the Danish medical doctor Niels Harboe in 1966 and has 40 years' experience in the development and production of reagents and antibodies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2003 2 NIH $925,578
Project Title: Flow Cytometric Analysis Of Genotoxicity

Key People / Management

  Nigel M Ferrey -- President

  Dawn Mayer

  Johnathan C Sharpe

Company News

There are no news available.